On Friday, Shares of Williams Companies Inc (NYSE:WMB), lost -1.94% to $46.43.
Williams, declared it has placed into service a major expansion of its Transco natural gas pipeline to fuel new electric-power generation in Virginia and serve increasing local distribution demand in North Carolina. Transco is the nation’s largest-volume and fastest-growing interstate natural gas pipeline system with enough transportation capacity to serve the equivalent of more than 50 million households each day in North America.
The about $300 million Virginia Southside Expansion is providing 270,000 dekatherms per day (dth/d) of incremental transportation capacity, which is enough gas to serve the equivalent of 1.6 million households. The expansion comprises of about 100 miles of new, 24-inch diameter pipeline extending from the Transco mainline in Pittsylvania County, Va., and into Halifax, Charlotte, Mecklenburg, and terminating in Brunswick County, Va. Transco placed the majority of the pipe parallel to its own existing pipeline, alongside an existing utility corridor. In addition, Transco added more than 21,000 horsepower of compression at Station 165 in Pittsylvania County, Va.
“From New York City to the Gulf Coast, we are executing on unprecedented growth on our Transco system as customers continue to seek opportunities to connect to long-lived U.S. natural gas reserves,” said Rory Miller, senior vice president of Williams Partners’ Atlantic-Gulf operating area. “As we work to connect the best supplies to the best markets, we are sharply focused on bringing these large-scale projects into service on time and on budget. These key expansions to our already premier infrastructure base are driving noteworthygrowth in our fee-based revenues and creating shareholder value.”
The Williams Companies, Inc. operates as an energy infrastructure company primarily in the United States. The company operates in three segments: Williams Partners, Access Midstream, and Williams NGL & Petchem Services. It owns and operates natural gas pipeline system extending from Texas, Louisiana, Mississippi, and the offshore Gulf of Mexico through Alabama, Georgia, South Carolina, North Carolina, Virginia, Maryland, Delaware, Pennsylvania, and New Jersey to the New York City metropolitan area.
Shares of Trevena Inc (NASDAQ:TRVN), inclined 8.80% to $10.76, during its last trading session.
Trevena, declared positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events.
“The data from this trial showed that TRV130, when given on-demand, matched morphine efficacy for pain relief with a markedly improved safety and tolerability profile,” said Neil Singla, M.D., chief scientific officer of Lotus Clinical Research and lead investigator of the study. “The challenges of safely and adequately titrating morphine are well recognized, and these data suggest that, if approved, TRV130 may provide a better option than presently available opioid analgesics.”
In the trial, two regimens of TRV130 were tested: the first compriseed of a 1.5 mg intravenous loading dose with 0.1 mg self-administered on-demand doses as often as every 6 minutes (together referred to here as “TRV130 0.1 mg”) using a patient controlled analgesia (PCA) device; the second compriseed of a 1.5 mg loading dose with 0.35 mg on-demand doses (together referred to here as “TRV130 0.35 mg”) using a PCA device. A commonly used morphine PCA regimen was also tested, compriseing of a 4 mg loading dose with 1 mg on-demand doses. Placebo was administered as a loading dose and on-demand doses that were volume-matched to the active regimens.
Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The companys central nervous system product pipeline comprises TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain.
Finally, CyberArk Software, Ltd. (NASDAQ:CYBR), ended its last trade with -1.12% loss, and closed at $62.66.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
